IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome
- PMID: 9708542
- DOI: 10.1002/ana.410440210
IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome
Abstract
To investigate the pathophysiological role of anti-GM1 antibody in Guillain-Barré syndrome (GBS), we reviewed sequential nerve conduction studies of 345 nerves in 34 GBS patients. Statistically significant correlation between IgG anti-GM1 antibodies and electrodiagnoses was found. Sixteen IgG anti-GM1-positive patients were classified as having acute motor or acute motor sensory axonal neuropathy (AMAN or AMSAN) (12 patients), as having acute inflammatory demyelinating polyneuropathy (AIDP) (3 patients), or as undetermined (1 patient) by electrodiagnostic criteria. Besides axonal features, there was rapid resolution of conduction slowing and block. In 3 patients initially diagnosed as having AIDP, conduction slowing was resolved within days, and 1 of them and 3 AMAN patients showed markedly rapid increases in amplitudes of distal compound muscle action potentials that were not accompanied by prolonged duration and polyphasia. The time courses of conduction abnormalities were distinct from those in IgG anti-GM1-negative AIDP patients. Rapid resolution of conduction slowing and block, and the absence of remyelinating slow components, suggest that conduction failure may be caused by impaired physiological conduction at the nodes of Ranvier. Reversible conduction failure as well as axonal degeneration constitutes the pathophysiological mechanisms in IgG anti-GM1-positive GBS. In both cases, immune-mediated attack probably occurs on the axolemma of motor fibers.
Similar articles
-
Conduction block in acute motor axonal neuropathy.Brain. 2010 Oct;133(10):2897-908. doi: 10.1093/brain/awq260. Epub 2010 Sep 20. Brain. 2010. PMID: 20855419
-
GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome.Neurology. 2008 Nov 18;71(21):1683-90. doi: 10.1212/01.wnl.0000335160.72184.7d. Neurology. 2008. PMID: 19015484
-
Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan.Ann Neurol. 2000 Oct;48(4):624-31. Ann Neurol. 2000. PMID: 11026446
-
Axonal Guillain-Barré syndrome: carbohydrate mimicry and pathophysiology.J Peripher Nerv Syst. 2007 Dec;12(4):238-49. doi: 10.1111/j.1529-8027.2007.00153.x. J Peripher Nerv Syst. 2007. PMID: 18042134 Review.
-
Electrodiagnostic criteria for Guillain-Barrè syndrome: a critical revision and the need for an update.Clin Neurophysiol. 2012 Aug;123(8):1487-95. doi: 10.1016/j.clinph.2012.01.025. Epub 2012 Apr 4. Clin Neurophysiol. 2012. PMID: 22480600 Review.
Cited by
-
Guillain-Barré syndrome: epidemiology, pathophysiology and management.Drugs. 2004;64(6):597-610. doi: 10.2165/00003495-200464060-00003. Drugs. 2004. PMID: 15018590 Review.
-
Clinical features of Guillain-Barré syndrome patients with elevated serum creatine kinase levels.BMC Neurol. 2020 May 27;20(1):214. doi: 10.1186/s12883-020-01796-z. BMC Neurol. 2020. PMID: 32460711 Free PMC article.
-
Neuro-glial interactions at the nodes of Ranvier: implication in health and diseases.Front Cell Neurosci. 2013 Oct 29;7:196. doi: 10.3389/fncel.2013.00196. Front Cell Neurosci. 2013. PMID: 24194699 Free PMC article. Review.
-
Real time imaging of intra-axonal calcium flux in an explant mouse model of axonal Guillain-Barré syndrome.Exp Neurol. 2022 Sep;355:114127. doi: 10.1016/j.expneurol.2022.114127. Epub 2022 May 29. Exp Neurol. 2022. PMID: 35640716 Free PMC article.
-
Mechanisms of distal axonal degeneration in peripheral neuropathies.Neurosci Lett. 2015 Jun 2;596:33-50. doi: 10.1016/j.neulet.2015.01.048. Epub 2015 Jan 21. Neurosci Lett. 2015. PMID: 25617478 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources